Deutsche Bank AG Invests $1.67 Million in AtriCure, Inc. $ATRC

Deutsche Bank AG acquired a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC) during the second quarter, HoldingsChannel reports. The fund acquired 59,668 shares of the medical device company’s stock, valued at approximately $1,670,000.

A number of other hedge funds also recently made changes to their positions in the stock. Rice Hall James & Associates LLC purchased a new stake in AtriCure in the 2nd quarter worth approximately $3,755,000. Global Retirement Partners LLC purchased a new position in AtriCure during the second quarter valued at approximately $52,000. Bank of New York Mellon Corp bought a new position in shares of AtriCure in the second quarter worth approximately $3,953,000. Handelsbanken Fonder AB boosted its position in shares of AtriCure by 12.3% in the second quarter. Handelsbanken Fonder AB now owns 22,800 shares of the medical device company’s stock worth $638,000 after purchasing an additional 2,500 shares during the period. Finally, Tactive Advisors LLC purchased a new stake in shares of AtriCure in the second quarter worth $374,000. 99.11% of the stock is currently owned by institutional investors.

AtriCure Stock Performance

AtriCure stock opened at $48.54 on Friday. The company’s 50-day moving average price is $37.89 and its 200-day moving average price is $32.26. AtriCure, Inc. has a twelve month low of $25.36 and a twelve month high of $49.98. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. The company has a market cap of $2.47 billion, a PE ratio of 231.15 and a beta of 1.20.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The firm had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same quarter last year, the firm earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities research analysts forecast that AtriCure, Inc. will post 0.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ATRC shares. Canaccord Genuity Group raised their price objective on shares of AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Weiss Ratings upgraded AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 19th. Piper Sandler raised their price target on AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday. Wall Street Zen cut AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, UBS Group lowered their price objective on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $49.89.

Insider Buying and Selling at AtriCure

In other news, insider Karl S. Dahlquist sold 9,370 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $48.89, for a total value of $458,099.30. Following the completion of the sale, the insider directly owned 87,319 shares of the company’s stock, valued at $4,269,025.91. This trade represents a 9.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Maggie Yuen sold 3,500 shares of AtriCure stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total value of $134,470.00. Following the completion of the transaction, the director owned 14,015 shares of the company’s stock, valued at approximately $538,456.30. This trade represents a 19.98% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 53,616 shares of company stock valued at $2,149,994. Corporate insiders own 4.00% of the company’s stock.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.